BioCentury | Jul 25, 2019
Distillery Therapeutics

A tumor-targeted Bavencio conjugate with enhanced antitumor efficacy

...Shenzhen, China e-mail: joshuacao@pku.edu.cn CONTACT: Feng Wang, Chinese Academy of Sciences, Beijing, China e-mail: wangfeng@ibp.ac.cn Inhua Muijrers-Chen Alpha melanocyte stimulating hormone (alpha-MSH) Melanocortin...
BioCentury | Jun 3, 2019
Company News

June 3 Company Quick Takes: EU pharmas form consortium to predict late-stage success; plus Lilly/Atomwise, Gilead/HitGen, Emergent and more

...FDA required more time to review its NDA for the sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Sep 28, 2015
Clinical News

Scenesse afamelanotide regulatory update

...a disease registry. Last December, the European Commission approved the sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Feb 16, 2015
Clinical News

Scenesse afamelanotide regulatory update

...12 patients and submit periodic safety reports to EMA. The sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Nov 17, 2014
Company News

Clinuvel, Biotech Lab Singapore deal

...skin. Scenesse is a sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone (MSH) and CUV9900 is an alpha melanocyte stimulating hormone (alpha-MSH)...
BioCentury | Oct 27, 2014
Clinical News

Scenesse afamelanotide regulatory update

...in the U.S., EU, Australia and Switzerland for EPP. The sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Oct 25, 2014
Company News

CHMP recommends Clinuvel's Scenesse

...pain-free direct sunlight exposure over an eight-hour period. Scenesse, a sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Sep 29, 2014
Clinical News

Scenesse afamelanotide regulatory update

...absolute ultraviolet radiation and light intolerance in the skin. The sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Aug 11, 2014
Company News

Clinuvel, Retrophin deal

...plaque-like lesions and blisters on areas where skin folds. The sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
BioCentury | Jun 9, 2014
Clinical News

Scenesse afamelanotide: Phase II started

...Business: Dermatology Molecular target: Melanocortin 1 receptor (MC1R) Description: Sustained-release subcutaneous implant of synthetic alpha melanocyte stimulating hormone...
Items per page:
1 - 10 of 112